Sponsor-Investigators

Nabil Adra

HCRN-GU17-295

A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma

Status

Closed

Cancer Types

Bladder

Locations